|
gptkbp:instance_of
|
gptkb:television_channel
|
|
gptkbp:bfsLayer
|
7
|
|
gptkbp:bfsParent
|
gptkb:Digoxin
|
|
gptkbp:activities
|
Calcium channel inhibition
|
|
gptkbp:approves
|
gptkb:legislation
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:brand
|
gptkb:Isoptin
gptkb:Verelan
Calan
|
|
gptkbp:class
|
Vasodilator
Antiarrhythmic agent
Antihypertensive agent
|
|
gptkbp:clinical_trial
|
Phase IV
Phase II
Phase III
Phase I
|
|
gptkbp:contraindication
|
Cardiogenic shock
Severe hypotension
Severe left ventricular dysfunction
|
|
gptkbp:developed_by
|
gptkb:Knoll_Pharmaceuticals
|
|
gptkbp:discovered_by
|
1960s
|
|
gptkbp:dosage_form
|
120 mg per day
240 mg per day
240-320 mg per day
80-480 mg per day
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Verapamil
|
|
gptkbp:ingredients
|
C27 H38 N2 O5
|
|
gptkbp:interacts_with
|
gptkb:Digoxin
Antidepressants
Statins
Beta blockers
|
|
gptkbp:is_atype_of
|
C08 D A01
|
|
gptkbp:is_available_on
|
gptkb:tablet
Injection
|
|
gptkbp:is_used_for
|
gptkb:Supraventricular_tachycardia
Hypertension
Angina pectoris
|
|
gptkbp:lifespan
|
5 to 12 hours
|
|
gptkbp:manager
|
Intravenous
Oral
|
|
gptkbp:metabolism
|
Liver
|
|
gptkbp:side_effect
|
gptkb:Nausea
Dizziness
Headache
Constipation
|
|
gptkbp:type_of
|
52-53-9
|
|
gptkbp:was_marked_by
|
gptkb:Calan_SR
gptkb:Isoptin_SR
gptkb:Verelan_PM
|